US09061G1013
US09061G1013
BioMarin Pharmaceutical Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±33.0% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).
Beta (Market Relation)
0.22x
DefensiveVolatility (5Y p.a.)
33.0% p.a.
5-Year HorizonMax Drawdown (5Y)
-57.6%
5-Year HorizonSharpe Ratio
-0.28
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +0.4% |
| 3 Years | 33.3% | -49.8% | -0.5 | -14.2% |
| 5 Years | 33.0% | -57.6% | -0.28 | -6.7% |
| 10 Years | 35.0% | -62.1% | -0.22 | -5.2% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 148.1 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (33.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -62.1% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
2 ISS Score: 2 / 10
Audit Risk
4 ISS Score: 4 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
5.62